IE
ZNTL icon

Israel Englander’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Israel Englander’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30,000
Closed -$1.38M – 7595
2022
Q1 		$1.38M Buy
+30,000
New +$1.62M ﹤0.01% 4216

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Israel Englander's ZNTL Position: Q2 2026 in Review

Israel Englander reduced its Zentalis Pharmaceuticals (ZNTL) stake by 48% in Q2 2026, selling an estimated $2.5M and leaving 664,281 shares worth $3.22M. The position accounts for ﹤0.01% of the portfolio, ranked #3398.

Israel Englander first reported a position in ZNTL in Q1 2021 and has held it in 19 quarters since. The position peaked at $8.97M in Q3 2023. 113 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Israel Englander held 664,281 shares of Zentalis Pharmaceuticals worth $3.22M as of Q2 2026.
  • Israel Englander sold 625,541 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $2.5M.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3398 holding.
  • Israel Englander first reported a position in Zentalis Pharmaceuticals in Q1 2021 and has held it in 19 quarters since.
  • Israel Englander's Zentalis Pharmaceuticals position peaked at $8.97M in Q3 2023.
  • 113 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.